The reversal of multidrug resistance in ovarian carcinoma cells by co-application of tariquidar and paclitaxel in transferrin-targeted polymeric micelles

Journal of Drug Targeting

Volumn 25, Issue 3, 2017, Pages 225-234

  Zou, Wanting ^a   Sarisozen, Can ^b   Torchilin, Vladimir P ^b,c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b NORTHEASTERN UNIVERSITY   (United States)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Co delivery; micelles; multidrug resistance; P glycoprotein; targeted drug delivery; transferrin

Indexed keywords

ALPHA TOCOPHEROL; CAVEOLIN; CHLORPROMAZINE; CLATHRIN; CYTOCHALASIN D; GENISTEIN; PACLITAXEL; TARIQUIDAR; TRANSFERRIN; ANTINEOPLASTIC AGENT; POLYMER; QUINOLINE DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; ENCAPSULATION; ENDOCYTOSIS; FEMALE; FLOW CYTOMETRY; HUMAN; HYDRODYNAMICS; INTERNALIZATION; INTRACELLULAR SIGNALING; MICELLE; MULTIDRUG RESISTANCE; OVARY CARCINOMA; PHOTON CORRELATION SPECTROSCOPY; PINOCYTOSIS; POLYMERIZATION; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ZETA POTENTIAL; CHEMISTRY; DRUG EFFECTS; OVARY TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; MICELLES; OVARIAN NEOPLASMS; PACLITAXEL; POLYMERS; QUINOLINES;

EID: 84989878910     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/1061186X.2016.1236113     Document Type: Article

References (35)

1. Stein WD, Bates SE, Fojo T., Intractable cancers:the many faces of multidrug resistance and the many targets it presents for therapeutic attack. Current Drug Targets 2004;5:333–46.
2. Burger H, Foekens JA, Look MP, et al. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer:correlation with chemotherapeutic response. Clin Cancer Res 2003;9:827–36.
3. Gregorcyk S, Kang Y, Brandt D, et al. p-Glycoprotein expression as a predictor of breast cancer recurrence. Ann Surg Oncol 1996;3:8–14.
4. Arts HJG, Katsaros D, de Vries EGE, et al. Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin Cancer Res 1999;5:2798–805.
5. Materna V, Pleger J, Hoffmann U, Lage H., RNA expression of MDRI/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients:correlation with chemotherapeutic response. Gynecol Oncol 2004;94:152–60.
6. Clarke R, Leonessa F, Trock B., Multidrug resistance/P-glycoprotein and breast cancer:review and meta-analysis. Semin Oncol 2005;32:S9–S15.
7. Torres K, Horwitz SB., Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res 1998;58:3620–6.
8. Patel NR, Rathi A, Mongayt D, Torchilin VP., Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes. Int J Pharm 2011;416:296–9.
9. Patil Y, Sadhukha T, Ma L, Panyam J., Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J Control Release 2009;136:21–9.
10. Palmeira A, Sousa E, Vasconcelos MH, Pinto MM., Three decades of P-gp inhibitors:skimming through several generations and scaffolds. Curr Med Chem 2012;19:1946–2025.
11. Mistry P, Stewart AJ, Dangerfield W, et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res 2001;61:749–58.
12. Assaraf YG, Borgnia MJ., Differential reversal of lipophilic antifolate resistance in mammalian-cells with modulators of the multidrug-resistance phenotype. Anti-Cancer Drugs 1993;4:395–406.
13. Gottesman MM, Fojo T, Bates SE., Multidrug resistance in cancer:role of ATP-dependent transporters. Nature Rev Cancer 2002;2:48–58.
14. Sarkadi B, Homolya L, Szakacs G, Varadi A., Human multidrug resistance ABCB and ABCG transporters:participation in a chemoimmunity defense system. Physiol Rev 2006;86:1179–236.
15. Sauna ZE, Smith MM, Muller M, et al. The mechanism of action of multidrug-resistance-linked P-glycoprotein. J Bioenergetics Biomembranes 2001;33:481–91.
16. Martin C, Berridge G, Mistry P, et al. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol 1999;128:403–11.
17. Gupta P, Jani KA, Yang DH, et al. Revisiting the role of nanoparticles as modulators of drug resistance and metabolism in cancer. Expert Opin Drug Metabol Toxicol 2016;12:281–9.
18. Chang J, Paillard A, Passirani C, et al. Transferrin adsorption onto PLGA nanoparticles governs their interaction with biological systems from blood circulation to brain cancer cells. Pharm Res-Dordr 2012;29:1495–505.
19. Sahoo SK, Ma W, Labhasetwar V., Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int J Cancer 2004;112:335–40.
20. Shah N, Chaudhari K, Dantuluri P, et al. Paclitaxel-loaded PLGA nanoparticles surface modified with transferrin and Pluronic((R))P85, an in vitro cell line and in vivo biodistribution studies on rat model. J Drug Target 2009;17:533–42.
21. Sarisozen C, Vural I, Levchenko T, et al. PEG-PE-based micelles co-loaded with paclitaxel and cyclosporine A or loaded with paclitaxel and targeted by anticancer antibody overcome drug resistance in cancer cells. Drug Deliv 2012;19:169–76.
22. Dabholkar RD, Sawant RM, Mongayt DA, et al. Polyethylene glycol-phosphatidylethanolamine conjugate (PEG-PE)-based mixed micelles:some properties, loading with paclitaxel, and modulation of P-glycoprotein-mediated efflux. Int J Pharm 2006;315:148–57.
23. Sarisozen C, Abouzeid AH, Torchilin VP., The effect of co-delivery of paclitaxel and curcumin by transferrin-targeted PEG-PE-based mixed micelles on resistant ovarian cancer in 3-D spheroids and in vivo tumors. Eur J Pharm Biopharm 2014;88:539–50.
24. Douglas KL, Piccirillo CA, Tabrizian M., Cell line-dependent internalization pathways and intracellular trafficking determine transfection efficiency of nanoparticle vectors. Eur J Pharm Biopharm 2008;68:676–87.
25. Ivanov AI, Pharmacological inhibition of endocytic pathways:Is it specific enough to be useful? In:Ivanov AI, editor. Methods in Molecular Biology. 4402008. p. 15–33.
26. Vercauteren D, Vandenbroucke RE, Jones AT, et al. The use of inhibitors to study endocytic pathways of gene carriers:optimization and pitfalls. Mol Ther 2010;18:561–9.
27. Guo L, Zhang H, Wang F, et al. Targeted multidrug-resistance reversal in tumor based on PEG-PLL-PLGA polymer nano drug delivery system. Int J Nanomed 2015;10:4535–47.
28. Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. Nature 2013;502:333.
29. Patch A-M, Christie EL, Etemadmoghadam D, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature 2015;521:489–U58.
30. Vinci M, Gowan S, Boxall F, et al. Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. BMC Biol 2012;10:29.
31. Loessner D, Stok KS, Lutolf MP, et al. Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells. Biomaterials 2010;31:8494–506.
32. Sodek KL, Ringuette MJ, Brown TJ., Compact spheroid formation by ovarian cancer cells is associated with contractile behavior and an invasive phenotype. Int J Cancer 2009;124:2060–70.
33. Friedrich J, Seidel C, Ebner R, Kunz-Schughart LA., Spheroid-based drug screen:considerations and practical approach. Nature Protocols 2009;4:309–24.
34. Al-Abd AM, Aljehani ZK, Gazzaz RW, et al. Pharmacokinetic strategies to improve drug penetration and entrapment within solid tumors. J Control Release 2015;219:269–77.
35. Perche F, Patel NR, Torchilin VP., Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEG-PE micelles in ovarian cancer cell spheroid model. J Control Release 2012;164:95–102.